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Background: Infections caused by extended spectrum beta-lactamases (ESBL)-producing bacteria have been
emerging worldwide and the majority of ESBL-producing E. coli strains are isolated from patients with urinary tracts
infections. The purpose of this study was to compare the host-response mechanisms in human
polymorphonucleated leukocytes (PMN) and renal epithelial cells when stimulated by ESBL- or non-ESBL-producing
uropathogenic E. coli (UPEC) isolates. The host-pathogen interaction of these ESBL-producing strains in the urinary
tract is not well studied.
Results: The ability of ESBL strains to evoke ROS-production from PMN cells was significantly higher than that of
the non-ESBL strains. The growth of ESBL strains was slightly suppressed in the presence of PMN compared to
non-ESBL strains after 30 min and 2 h, but the opposite was observed after 5 and 6 h. The number of migrating
PMN was significantly higher in response to ESBL strains compared to non-ESBL strains. Stimulation of A498 cells
with ESBL strains elicited lower production of IL-6 and IL-8 compared to non-ESBL strains.
Conclusion: Significant differences in host-response mechanisms were identified when host cells were stimulated
by ESBL- or non-ESBL producing strains. The obtained results on the early interactions of ESBL-producing strains
with the host immune system may provide valuable information for management of these infections.
Keywords: Extended spectrum beta-lactamases, Urinary tract infections, Renal epithelial cells, Polymorphonucleated
leukocytes, Uropathogenic E. coliBackground
Antibiotic resistance is an emerging health issue that
poses a serious threat to public health worldwide. Ex-
tended spectrum beta-lactamases (ESBL) are enzymes able
to inactivate beta-lactam antibiotics such as penicillins,
cephalosporins and monobactams by hydrolysis. ESBL are
defined as enzymes that can be transferred, mainly on
plasmids, hydrolyse third generation cephalosporins and
are inhibited by clavulanic acid, tazobactam or sulbactam
[1]. There are three major groups of ESBL enzymes; TEM,
SHV and CTX-M and these can be further divided into
subgroups. ESBL enzymes are predominantly found* Correspondence: isak.demirel@oru.se
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reproduction in any medium, provided the orin the bacterial species Klebsiella pneumoniae and
Escherichia coli but may also be found in other species of
Enterobacteriaceae. These bacteria are common causes of
urinary tract infections (UTI) and may also cause sepsis,
respiratory tract- and intra-abdominal infections [1].
ESBL-producing organisms have previously been associ-
ated with nosocomial infections but community-acquired
infections mainly due to CTX-M-producing E. coli are
emerging [2]. The majority of all ESBL-producing bacteria
are isolated from urine samples and most of these
bacteria are E. coli [3]. Treatment of infections caused
by ESBL-producing bacteria is often complicated due
to concomitant resistance to other classes of antibiotics
such as fluoroquinolones, aminoglycides, trimethoprim/l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ESBL-producing uropathogenic bacteria has increased in
the last decades. In southern Europe, 21% of the commu-
nity [5] and 18% of the nosocomial [6] urinary tract infec-
tions (UTI) are caused by ESBL-producing E. coli.
The host-responses to infection by uropathogenic E. coli
(UPEC) are characterized by neutrophil migration into the
tissue and production of pro-inflammatory cytokines [7].
The early response of effector cells such as uroepithelial
cells and neutrophils to UPEC may influence bacterial
clearance and thereby the outcome of the infection. It is
not yet established whether ESBL-producing isolates have
different virulence properties or pathogenic potentials
than non-ESBL producers. Studies performed on expres-
sion of virulence factors and phylogenetic groups among
ESBL-producing E. coli strains have not been conclu-
sive [2,8]. Furthermore, data on the effect of ESBL-
producing strains on activation of host effector cells are
limited. Some studies have showed that ESBL-producing
K. pneumoniae are able to impair the respiratory burst of
polymorphonuclear leukocytes (PMN) [9] and have a
higher ability to invade ileocecal- and bladder epithe-
lium [10] compared to non-ESBL-producing strains. A
higher proportion of ESBL-producing K. pneumoniae
strains were reported to be serum-resistant and there-
fore able to withstand the bactericidal effect of serum [11].
ESBL-producing E. coli have been reported to stimulate
higher production of pro-inflammatory cytokines from
human monocytes compared to susceptible E. coli [12].
It is well known that UPEC can stimulate pro-inflammatory
pathways, but recent studies indicate that some UPEC
strains have the ability to suppress activation of host-
response mechanisms. UPEC were demonstrated to
suppress production of pro-inflammatory cytokines from
bladder epithelial cells [13,14] and attenuated neutrophil
migration [15] compared to non-pathogenic E .coli strains.
It is not known if ESBL-producing UPEC strains have an
enhanced ability to modulate the host-response and evade
the immune system or if they are successful in establishing
infections only because of their antibiotic resistance. Thus,
it remains to be established how ESBL-producing UPEC
interact with the host immune system in the urinary tract.
The purpose of this study was to compare activation of
host-response mechanisms in human PMN and renal
epithelial cells when infected by ESBL- or non-ESBL-
producing UPEC strains.
Methods
Bacterial isolates, cell line and culturing conditions
Eight ESBL-producing and 11 non-ESBL-producing
(susceptible) E. coli, isolated from standard patient
care individuals with suspected pyelonephritis, were
obtained from the Department of Microbiology at Örebro
University hospital, Sweden. The identity of the patientswas anonymized and after that further analyses of the
strains were performed. Antimicrobial susceptibility test-
ing was performed as recommended by the Swedish
Reference Group for Antibiotics (www.srga.org) and the
isolates were genetically characterized for CTX-M, TEM
and SHV type by real time PCR and nucleotide sequen-
cing and stored as previously described [16]. MG1655, a
well-characterized and non-pathogenic E. coli K-12 strain
and CFT073, a UPEC strain isolated from a patient
with pyelonephritis, were used as control strains. The
bacteria were cultured on tryptic soy agar (TSA) over-
night at 37°C prior to any experiment. Colonies were
suspended in phosphate buffered saline (PBS) to the ap-
propriate concentrations.
A498 cells (HTB-44, ATCC) are human renal epithelial
cells derived from a kidney carcinoma. A498 cells were
cultured in Dulbecco's modified eagle medium (DMEM,
Sigma-Aldrich, St. Louis, MO, USA) containing 10%
fetal bovine serum (FBS), 1 mM non-essential amino
acids, 2 mM L-glutamine, 50 U/ml penicillin and 50 μl/ml
streptomycin (all from Invitrogen Ltd, Paisley, UK) at 5%
CO2 and 37°C. Prior to the experiment the cell-culturing
medium was replaced with DMEM containing 2% FBS,
1 mM non-essential amino acids and 2 mM L-glutamine
(penicillin and streptomycin were excluded).
Phylogenetic analysis of E. coli strains by real-time PCR
DNA was isolated from 2–3 colonies grown on TSA
plates. The colonies were suspended in 100 μl sterile
water and the suspensions were boiled for 15 min,
cooled to 4°C and subsequently centrifuged for 30 s at
12 000 × g. The amplification was performed by using
10 μl SsoFast EvaGreen® Supermix (Bio-Rad laboratories,
CA, USA), 2 μl of primer (250 nM), 2 μl genomic DNA (in
total 50 ng) and 6 μl water. All primers were ordered from
Eurofins MWG Synthesis GmbH (Ebersberg, Munich,
Germany). The amplification was performed in CFX96
Real-time thermocycler (Biorad Laboratories, Hercules,
CA, USA) as previously described [17].
Viability of A498 cells stimulated with E. coli
The A498 cell line was stimulated with the different bac-
terial isolates and the viability of the cells was assessed
after 6 h. Multiplicity of infection (MOI) of 10 was used
(5 · 105 cells were stimulated with 5 · 106 CFU of bac-
teria). The viability of the cells was assessed by the try-
pan blue (0.4%) exclusion test in a cell counter (TC10™
automated cell counter, Bio-Rad) and by the cytotoxicity
detection kit plus-LDH (Roche Diagnostics, Indianapolis,
IN, USA) according to manufacturer's protocol.
Isolation of polymorphonucleated leukocytes
Human polymorphonucleated leukocytes (PMN) were
isolated from whole blood using polymorphprep (Axis-
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according to the swedish national board of health and
welfares guidelines and the ethical guidelines of the dec-
laration of Helsinki. The healthy volunteers gave a writ-
ten informed consent for research use and the samples
were anonymized immediately after collection. The do-
nors were not subjected to extra harm or risk as the
blood was collected at the same occasion as a blood
donation. According to paragraph 4 of the swedish
law (2003:460) on ethical conduct in human research,
this study did not require ethical approval. Briefly,
polymorphprep was layered with an equal volume of hep-
arinized blood and centrifuged at 1350 rpm for 40 min at
room temperature. The PMN fraction was collected and
an equal volume of 0.45% NaCl and 20 ml PBS was added.
Any remaining erythrocytes were removed by hypotonic
lysis with sterile milliQ water. Cold PBS containing 3.4%
NaCl and Krebs-Ringer glucose (KRG) were added to
restore osmotic pressure. The PMN were centrifuged,
the supernatant discarded and the pellet resuspended in 1
ml PBS, KRG + Ca2+ or DMEM + 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES). The viability of
the PMN was > 90% as determined by the trypan blue
exclusion test.
Measurement of total ROS-production
Total reactive oxygen species (ROS)-production of PMN
was measured with a luminol-horseradish peroxidase
(HRP) assay. Luminol is activated by H2O2 and the evoked
luminescence is proportional to ROS-production. PMN in
KRG+Ca2+ were incubated with luminol (0.1 mg/ml,
Sigma) and HRP (4 U/ml, Roche) for 15 min at 5% CO2
and 37°C. PMN and bacteria (MOI 10) were com-
bined in a 96-well plate. Phorbol-12-myristat-13-acetat
(PMA) was used as positive control and KRG + Ca2+
as negative control. The plate was centrifuged at 400 × g
at 4°C for 3 min and the luminescence was measured in a
microplate reader (Fluostar Optima, BMG Labtech, Ayles-
bury, UK) every third min for 4 h. All samples were run in
duplicate.
Measurement of bacterial growth
PMN and bacteria (MOI 10) were combined in a 96-well
plate in cell culturing medium (DMEM+HEPES). As a
control, bacteria were grown in an equal volume of cell
culturing medium. The plate was incubated at 5% CO2
and 37°C and the absorbance was measured in a
microplate reader (Multiska Ascent, Thermo labsystems,
Helsingfors, Finland) at 620 nm every 30 min for 6 h.
The absorbance of PMN cells only was measured and
subtracted from the absorbance of the co-incubated
samples (bacteria + PMN). The relative growth inhibition
(delta OD620) was calculated as absorbance of bacteria-
(absorbance of bacteria + PMN). The viability of thePMN was > 80% as determined by trypan blue exclusion
test 6 h after bacterial stimulation.
Transwell PMN migration assay
A498 cells were seeded onto a inverted 3 μm pore size
transwell insert (Falcon, BD Biosciences Pharmingen,
San Diego, USA) for 3 h (at 5% CO2 and 37°C) to facili-
tate cell settling. After 3 h the inserts were placed in
6-well plates with fresh medium and the cells were cul-
tured on the inserts for 2 weeks at 5% CO2 and 37°C.
Medium was changed every second day. The cells were
pre-stimulated with the bacteria (MOI 10) for 4 h by
adding the different strains to the bottom wells. The
PMN were prepared as described above and 106 PMN
were added to the top well after the pre-stimulation.
PMN cells were collected from the bottom well after 1
and 3 h and counted in a cell counter (TC10™ automated
cell counter, Bio-Rad).
Measurement of epithelial cytokine production
An enzyme-linked immunosorbent assay (ELISA) was
performed to measure the cytokine production of A498
cells stimulated with different bacterial strains for 3 and
6 h. The cytokines IL-6 and IL-8 were measured using
human IL-8 and IL-6 kits (ELISA MAX™ Deluxe Sets,
BioLegend, San Diego, CA, USA).
Statistical analysis
The variables were normally distributed and differences
between groups were evaluated with the unpaired Student’s
t-test or one-way ANOVA followed by Bonferroni test.
Differences were considered statistically significant when
p < 0.05. Data were presented as mean ± standard error of
the mean (SEM), n = number of independent experiments.
Results
Selection and characterization of the UPEC strains
The renal epithelial (A498) cells were stimulated with
the different bacterial isolates for 6 h and the cell viabil-
ity was assessed. Bacterial isolates that decreased the cell
viability (> 20%) were not suitable for the in vitro infection
study design and were excluded. Two ESBL-producing
(2/8; 25%) and five non-ESBL-producing (5/11; 45%)
isolates were excluded based on this criteria. Six
ESBL-producing and six non-ESBL producing isolates
remained for investigation. The characteristics of the
different isolates included in the study are summarized in
Table 1. All ESBL-producing isolates belonged to either
the CTX-M-14 or CTX-M-15 enzyme type. The phylo-
genetic analysis showed that 50% of the susceptible strains
belonged to the B2, 33% to the B1 and 17% to the D
group. The majority of the ESBL-producing strains
belonged to the B2 group (83%) and the rest belonged to
the D group (17%) (Table 1).
Table 1 Characteristics of the bacterial isolates included in the study
Isolate ESBL type Phylogenetic group Antibiotic resistance
ESBL 2 CTX-M-14, TEM-1 B2 CTX, CAZ, CIP, MEC, TZP, TMP
ESBL 3 CTX-M-15, TEM-1 B2 CTX, CAZ, MEC, TZP, TMP
ESBL 5 CTX-M-15 B2 CTX, CAZ, CTB, CIP, TZP, TMP
ESBL 6 CTX-M-14 D CTX, CAZ, CTB
ESBL 7 CTX-M-15 B2 AmC, CTX, CAZ, CTB, CXM, CIP, SXT
ESBL 8 CTX-M-15 B2 CTX, CAZ, CTB, CIP, MEC, TZP
Susceptible 1 - B2 TMP
Susceptible 2 - B2 -
Susceptible 3 - B1 TMP
Susceptible 4 - B2 -
Susceptible 7 - B1 -
Susceptible 11 - D -
CTX Cefotaxime, CAZ Ceftazidime, CIP Ciprofloxacin, MEC, Mecillinam, TZP Pipeacillin/Tazobactam, TMP Timetoprim, CTB Ceftibuten, AmC Amoxicillin + Clavulanic
acid, CXM Cefuroxim, SXT Sulfamethoxazole/Trimetoprim.
Figure 1 ROS production induced by ESBL- and non-ESBL-producing
E. coli. Total ROS production in PMN stimulated by ESBL-producing
strains, susceptible E. coli strains, a positive control (PMA) and a
negative control (KRG) (A). The ROS production evoked by MG1655,
CFT073, a positive control (PMA, 5 μM) and a negative control (KRG)
(B). Data are presented as mean ± SEM luminescence (RLU) (n = 4-5
independent experiments).
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Production of ROS by PMN is a key characteristic of the
early host response to bacterial infections. The ESBL-
producing E. coli strains evoked higher ROS-production
compared to susceptible E. coli strains (p < 0.001) when
analyzing the sum ROS production for the whole 4 h
incubation period. The ROS-production induced by
ESBL- producing and susceptible strains followed the
same pattern with a low peak after 30 min and a higher
peak after 2 h (Figure 1A). The ROS-production of
PMN was markedly higher in cells stimulated with the
non-pathogenic strain MG1655 compared to those
stimulated with the UPEC strain CFT073. MG1655
induced a massive ROS-production after 30 min, ap-
proximately 5.5 times higher than the positive control
PMA (Figure 1B).
Growth response of ESBL- and non-ESBL-producing E. coli
incubated with PMN
We next examined whether the observed differences be-
tween ESBL- and susceptible strains in evoked ROS pro-
duction had any effects on the bacterial growth. The
bacterial growth response was inhibited in the presence
of PMN when compared to bacteria grown in the ab-
sence of PMN as shown in Figure 2A. In the presence
of PMN, the CFT073 strain showed recovered growth
after approximately 100 min while the growth of
MG1655 was suppressed for approximately 270 min
(Figure 2A). The growth of ESBL-producing E. coli
was slightly suppressed in the presence of PMN compared
to antibiotic susceptible E. coli after 30 min and 120 min
(p < 0.05) (Figure 2B). However, after 300 and 360 min the
growth of susceptible E. coli was slightly more suppressed
compared to ESBL-producing E. coli (p < 0.05). The growth
Figure 2 PMN induced growth inhibition of ESBL- and
non-ESBL-producing E. coli. Growth of MG1655 and CFT073
incubated with PMN (MOI 10) or without PMN (A). Relative growth
inhibition of MG1655, CFT073 and the mean relative growth
inhibition of susceptible and ESBL-producing E. coli. The relative
growth inhibition (delta OD620) is calculated as (absorbance of
bacteria-(absorbance of bacteria + PMN)) (B). Data are presented as
mean ± SEM (n = 3 independent experiments). Asterisks denote
statistical significance (*p < 0.05).
Figure 3 PMN migration across a renal epithelial cell line layer
in response to ESBL- and non-ESBL-producing E. coli. A498 cells
stimulated by the individual bacterial strains (A), and the mean
PMN migration across A498 cell layer stimulated with ESBL- and
non-ESBL-producing strains, CFT073 and MG1655 (MOI 10) (B). Data
are presented as mean ± SEM (n = 3 independent experiments).
Asterisks denote statistical significance (***p < 0.001).
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the other strains but the difference in growth inhibition be-
tween MG1655 and CFT073 did not reach statistical sig-
nificance (Figure 2B).
Transepithelial migration of PMN evoked by ESBL- and
non-ESBL-producing E. coli
A transepithelial migration assay was performed in order
to examine PMN migration evoked by the different
E. coli strains. The transwell cell monolayer showed
low levels of PMN migration in the absence of bacteria
(data not shown). All strains evoked PMN migration after
1 h but there were differences in their ability to attract the
PMN (Figure 3A). The ESBL-induced PMN migration
was significantly higher 1.6 ± 0.13 fold (p < 0.001) than the
migration induced by susceptible strains (Figure 3B). The
MG1655 strain induced a significant higher 3.3 ± 0.44 fold
(p < 0.001) migration than the CFT073 strain. MG1655
was also shown to attract the largest number of PMN
compared to the other strains (Figure 3B). There were nodifferences observed between ESBL-producing and sus-
ceptible strains in their ability to attract PMN after 3 h
(data not shown).
Epithelial cytokine production evoked by ESBL- and
non-ESBL-producing E. coli
The activation of pro-inflammatory cytokines from urin-
ary tract epithelial cells was evaluated. Both the ESBL-
producing and the susceptible strains induced a signifi-
cant higher IL-6 and IL-8 production from A498 cells
compared to unstimulated cells after 6 h. No significant
difference was observed between the ESBL- producing
and susceptible strains in their ability to induce cytokine
production after 3 h (data not shown). The IL-6 and IL-
8 production of A498 cells revealed differences between
the individual strains (Figures 4A and 5A) and notably,
strains that induced high IL-6 production did also in-
duce high IL-8 production. The cytokine production of
A498 cells incubated with ESBL-producing strains when
grouped together was significantly lower 28 ± 1.9% (IL-6)
and 52 ± 3.5% (IL-8) (p < 0.05) compared to cells stimu-
lated with susceptible strains (Figures 4B and 5B). The
non-pathogenic MG1655 strain induced a significantly
Figure 4 Induced IL-6 secretion of A498 cells in response to
ESBL- and non-ESBL-producing E. coli. IL-6 production from
A498 cells induced by the individual bacterial strains (A),
and the mean IL-6 production of A498 cells stimulated with
ESBL- and non-ESBL-producing strains, CFT073 and MG1655
(MOI 10) (B). Data are presented as mean ± SEM (n = 6 independent
experiments). Asterisks denote statistical significance (*p < 0.05,
**p < 0.01, ***p < 0.001).
Figure 5 Induced IL-8 secretion of A498 cells in response to
ESBL- and non-ESBL-producing E. coli. IL-8 production from A498
cells induced by the individual bacterial strains (A). The mean IL-8
production from A498 cells stimulated with susceptible and ESBL-
producing E. coli, CFT073 and MG1655 (MOI 10) (B). Data are
presented as mean ± SEM (n = 6 independent experiments).
Asterisks denote statistical significance (**p < 0.01).
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pathogenic CFT073 strain (Figures 4B and 5B).
Discussion
In the present study we used an in vitro infection model to
compare the host response evoked by ESBL-producing
strains with non-ESBL-producing strains isolated from pa-
tients with pyelonephritis. Two ESBL- producing and five
non-ESBL-producing-strains were excluded due to their
cytotoxic potential. Thus, the most cytotoxic strains were
not included in the study. However, the results suggest that
susceptible isolates are more cytotoxic than ESBL isolates
at least in vitro. Virulence factors such as toxins are known
to decrease host cell viability and their expression may
partly explain the observed differences in cytotoxicity.
Hemolysin, cytotoxic necrotizing factor 1 (CNF1) and se-
creted autotransporter toxin (sat) have all been shown to
be less prevalent in ESBL-producing E. coli strains than
susceptible isolates [8,18-20].
The ability of ESBL-producing E. coli to stimulate oxi-
dative burst and evoke ROS-production from PMN cells
was greater than that of the antibiotic susceptible strains.
In contrast to our findings, a recent report showed
that ESBL-producing K. pneumoniae induced lowerlevels of ROS-production from PMN compared to
non-ESBL-producing strains [9]. This indicates that there
could be species differences. It has been suggested that
one virulence phenotype of UPEC may have the ability
to suppress ROS-production from PMN which ultim-
ately could have an advantage in colonizing the urinary
tract [15]. Thus, our ROS-production experiments sug-
gest that ESBL-producing strains may be less virulent
than the susceptible strains. In support of a negative
correlation between ROS activation and virulence, the
non-pathogenic strain MG1655 was observed to induce
the highest levels of ROS compared to the pathogenic E.
coli strains.
To compare how ESBL-producing and susceptible
UPEC strains respond to the antimicrobial properties of
PMN the growth response of the isolates when incu-
bated with PMN was evaluated. In control experiments,
the growth of the non-pathogenic MG1655 strain was
markedly affected by co-incubation with PMN suggesting
that antimicrobial species such as ROS are released in our
assay. The fact that MG1655 induced the highest ROS-
production of all the examined strains may explain the
sustained growth inhibition. Some time-dependent differ-
ences in the growth of ESBL-producing and susceptible
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30 min and 2 h a slight increase in growth inhibition was
observed for the ESBL-producing strains. Interestingly, at
these time points ESBL-producing strains induced higher
ROS-production from PMN compared to the susceptible
strains, which may explain the observed differences in
growth inhibition. However, at 5 and 6 h the growth of
susceptible strains was slightly reduced compared to
ESBL-producing E. coli. Thus, it appears that the anti-
microbial effect evoked by PMN on ESBL-producing and
susceptible strains may vary over time. No differences in
the ability of PMN to kill ESBL- and non-ESBL-producing
K. penumoniae strains were reported in an earlier study
[9]. Differences in expression and activity of possible
resistance mechanism to antimicrobial factors may also
affect the growth outcome. It has been shown that
non-pathogenic E. coli are more sensitive to ROS ex-
posure, at least in the form of hydroxygen peroxide, than
uropathogenic CFT073 [15]. Moreover, UPEC strains have
been suggested to secrete effectors that interfere with pro-
inflammatory pathways which could decrease the phago-
cytic activity of PMN cells and partly explain the increased
tolerance compared to non-pathogenic strains [15,21,22].
Taken together, the higher evoked ROS production and
the trend in growth inhibition of ESBL-producing strains
in the early stages of infection may impair or delay the
establishment of infection by ESBL-producing strains.
An established in vitro transepithelial migration assay
with infected A498 cells [23,24] was used to compare
PMN migration evoked by ESBL-producing and suscep-
tible E. coli, respectively. The results showed that ESBL-
producing strains evoked higher PMN migration than
the susceptible strains. The non-pathogenic MG1655
strain induced a higher PMN migration than all of the
pathogenic strains which has been shown in a previous
study [15]. Bacterial suppression of neutrophil migration,
mediated by the periplasmatic protein YbcL, has been
proposed as an important trait used by uropathogens to
modulate host-response pathways [15]. Thus, the higher
PMN migration evoked by ESBL-producing strains com-
pared to susceptible strains might impair the propaga-
tion and colonization of ESBL strains in the urinary
tract. Again, ESBL-producing UPEC strains appear to be
less virulent than susceptible UPEC strains based on the
suggested association between low ability to suppress
neutrophil migration and low virulence [15].
The pro-inflammatory cytokines IL-6 and IL-8 are
produced by uroepithelial cells as part of the early im-
mune response and are important for the clearance of
the infection [25,26]. Production of IL-6 and IL-8 from
renal epithelial cells stimulated with ESBL-producing
strains was found to be lower than that of cells stimu-
lated with susceptible strains. In contrast to our results,
a recent study found that the IL-6 and IL-8 productionof monocytes stimulated by ESBL-producing E. coli was
higher compared to monocytes stimulated by susceptible
E. coli [12]. This suggests that ESBL-producing E. coli
strains have the ability to evoke diverse cytokine patterns
from different immunoactive cells. Recent studies have
shown that UPEC strains induce lower levels of the pro-
inflammatory cytokines IL-6 and IL-8 from bladder epi-
thelial cells than non-pathogenic K-12 strains [13,14] by
a mechanisms involving suppressed activation of the
pro-inflammatory NF-κB pathway [27]. In our study, the
UPEC strain CFT073 evoked minimal cytokine produc-
tion in support of a suppressive phenotype compared to
MG1655 as previously reported [13,14]. The ESBL-
producing and susceptible isolates showed variations in
their ability to induce IL-6 and IL-8 production. Strains
that failed to induce cytokines were found in both
groups but notably, among the strains that were able to
active cytokines, the cytokine levels were always higher
in cells infected by susceptible strains.
A limitation of the present study is that only few iso-
lates were used. However, the included isolates are likely
to be representative UPEC isolates as the majority of them
belonged to the B2 or D phylogenetic group [8,28]. In a
previous study (Önnberg et al., manuscript submitted)
the present ESBL-producing E. coli isolates were charac-
terized by using rep-PCR (DiversiLab [DL], bioMerieux,
Marcy l'Etoile, France). The isolates belonged to three
different DL-types and the predominant was DL-type 1
(67%). All DL-type 1 isolates belonged to the ST131 clone.
No correlation was found between the ability of the iso-
lates to stimulate ROS or cytokine production with the
CTX-M type, phylogenetic group or ST131 clone. Our
results are in agreement with previous observations that
CTX-M-producing isolates are dominated by the B2
phylogroup and the globally disseminated ST131 clone
[29,30]. Further studies are needed to characterize poten-
tial virulence factors, including type 1- and P-fimbriae and
capsular types among the clinical isolates. The newly iden-
tified virulence factor TcpC is of special interest. Some
UPEC strains have the ability to secrete effectors like TcpC
that are able to suppress innate immune responses, in-
cluding cytokine secretion from uroepithelial cells [22].
Taken together, if the capacity to suppress cytokine release
from uroepithelial cells can be regarded as a virulence
characteristic, ESBL-producing UPEC strains appear to be
more virulent than susceptible UPEC strains. This is in
contrast to the findings from experiments using PMN
where ESBL-producing strains appeared to have charac-
teristics supporting low virulence.
Increased knowledge and understanding of bacterial
virulence properties may be essential when identifying
novel therapeutic targets for multiresistant, ESBL-
producing Enterobacteriaceae. One virulence property
that has been recognized among UPEC strains is their
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[13-15]. The majority of the results in the present study
strengthens the argument that ESBL-producing E. coli
strains are less virulent than susceptible strains which
has been reported in previous genetic studies [8,28].
ESBL-producing E. coli have been reported to express
fewer virulence factors than susceptible isolates and
CTX-M-producers expressed fewer virulence factors than
other types of ESBL-producing E. coli [8,28]. In animal
models, infection with ESBL-producing E. coli showed
prolonged survival of the infected animals compared to
animals infected with susceptible bacteria [8,12]. The
prolonged survival time was correlated to a lower expres-
sion of virulence factors [8]. Knowledge of host-bacteria
interactions of importance for establishing urinary tract
infections by ESBL-producing strains may provide valu-
able information for improved management of these
emerging infections. Targeting bacterial virulence factors
is an alternative approach that offers opportunities to
inhibit pathogenesis and its consequences without
placing immediate life-or-death pressure on the target
bacterium [31]. Thus, by inhibiting specific mechanisms
that promote infection, e.g., adherens, toxin production,
invasion or subversion of host defences, new pharma-
ceutical tools effective against multiresistant pathogens
may be developed.
Conclusion
In the present study we conclude that differences in
evoked host-response mechanisms exist in vitro between
ESBL-producing and non-ESBL-producing UPEC strains.
More research is required to explain the mechanisms be-
hind these differences and also to find out whether differ-
ences exist between ESBL-producing and non-ESBL
producing UPEC strains in in vivo models of UTI.Competing interests
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